We’re pleased to share positive topline results from the Phase 2 study of CUE-221 in chronic spontaneous urticaria.
Join our conference call tomorrow, 9/21 at 8:00 a.m. EDT to learn more and see additional details in our press release here: https://t.co/5do6zPDO5r
I’m all about CUE being at conferencing and getting awareness out on CUE-221, CUE-401, and CUE-501; it’s what we need. But reading off a teleprompter and making mistakes reading does not deliver confidence… KNOW THE MATERIAL, BRING THE PASSION, AND BE CONFIDENT IN WHAT YOUR TALKING ABOUT…
@CueBiopharma@Jefferies Looking forward to this! Can we keep the PRs coming? Who’s the next board member we are showcasing? Let’s not go dark here.. we’ve got momentum behind us…
@andrewrsorkin if we are going to allow stock transfers to Trump Funds, they just transfer the stock to the government, the government sells the shares, the money goes into the Trump Funds equally and into the S&P500. The person who donates gets a charitable donation equal to that of the share value and the gains were $0.